- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00340275
Longitudinal Study of Vaginal Flora
30 juin 2017 mis à jour par: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Bacterial vaginosis is a syndrome manifested by adverse alterations in vaginal microbial flora.
It is present in 10 to 25% of women in the general population, and is the most common vaginal infection.
It has been associated with a number of adverse sequelae in reproductive health including acquisition of HIV, pelvic inflammatory disease, cervical dysplasia, and complications of gynecological procedures.
During pregnancy it has been associated with an increased risk of preterm birth an postpartum maternal infection.
However, the vaginal microbial flora remains poorly understood.
Information on variation in microbial flora and its association with BV from a longitudinal study is unavailable.
This prospective observational study aims to advance our knowledge of the natural history and abnormal alteration in vaginal microbial flora, and to identify risk factors that are associated with these changes.
A total of 5500 healthy, non-pregnant women of reproductive age will be enrolled and followed up in Birmingham, Alabama, for one year (baseline visit plus once every three months afterwards, totaling 5 visits).
Detailed information on sociodemographic status, medical history, hygiene practice, sexual behavior and psychosocial stress will be collected through in-person interviews.
Routine gynecological and dental examinations will be carried out during the study visits.
Samples of vaginal secretion and blood will be collected.
Laboratory tests to quantify vaginal microbial flora and to identify infection of bacterial vaginosis as well as common sexually transmitted diseases will be conducted.
This project is expected to complete in 5 years.
Aperçu de l'étude
Statut
Complété
Les conditions
Description détaillée
Bacterial vaginosis is a syndrome manifested by adverse alterations in vaginal microbial flora.
It is present in 10 to 25% of women in the general population, and is the most common vaginal infection.
It has been associated with a number of adverse sequelae in reproductive health including acquisition of HIV, pelvic inflammatory disease, cervical dysplasia, and complications of gynecological procedures.
During pregnancy it has been associated with an increased risk of preterm birth and postpartum maternal infection.
However, the vaginal microbial flora remains poorly understood.
Information on variation in microbial flora and its association with BV from a longitudinal study is unavailable.
This prospective observational study aims to advance our knowledge of the natural history and abnormal alteration in vaginal microbial flora, and to identify risk factors that are associated with these changes.
A total of 5500 healthy, non-pregnant women of reproductive age will be enrolled and followed up in Birmingham, Alabama, for one year (baseline visit plus once every three months afterwards, totaling 5 visits).
Detailed information on sociodemographic status, medical history, hygiene practice, sexual behavior and psychosocial stress will be collected through in-person interviews.
Routine gynecological and dental examinations will be carried out during the study visits.
Samples of vaginal secretion and blood will be collected.
Laboratory tests to quantify vaginal microbial flora and to identify infection of bacterial vaginosis as well as common sexually transmitted diseases will be conducted.
This project is expected to complete in 5 years.
Type d'étude
Observationnel
Inscription (Anticipé)
5500
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Alabama
-
Birmingham, Alabama, États-Unis
- University of Alabama
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
15 ans à 44 ans (Enfant, Adulte)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Femelle
La description
- ELIGIBILITY CRITERIA:
- Females, age 15-44.
- Since bacterial vaginosis is primarily a condition of reproductive-age women, this study will be restricted to women regarded by demographers as reproductive age.
- Non-pregnant women whose last menstrual period is later than expected will undergo a urine pregnancy test. Women who become pregnant while on study will complete their next regularly scheduled study visit, following which their participation will terminate.
EXCLUSION CRITERIA:
Immunocompromised status
Receiving or expected to receive in the next 12 months cytotoxic or immunosuppressive drugs.
Receiving or expected to receive in the next 12 months one or more 30-day courses of corticosteroids.
Congenital or acquired immune deficiency; known HIV positivity.
- Primary or secondary affective disorder, psychosis, emotional or intellectual limitations that preclude informed consent.
- Non-fluency in English.
- Post-menopausal (natural or surgical).
- Status post hysterectomy or expected to undergo hysterectomy in the next 12 months.
- Status post pelvic radiotherapy, or expected to undergo pelvic radiotherapy in the next 12 months.
- Receiving or expected to receive chronic (daily for at least 30 days) antibiotics in the next 12 months.
- Planning to move out of the area in the next 12 months.
- Participating or expected to participate during the next 12 months in a clinical trial in which antibiotics or topical microbicides will be administered in a blinded manner.
- Women who unexpectedly develop one of these conditions during their participation will continue to be followed, unless a specific contraindication arises.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Publications générales
- Goldenberg RL, Klebanoff MA, Nugent R, Krohn MA, Hillier S, Andrews WW. Bacterial colonization of the vagina during pregnancy in four ethnic groups. Vaginal Infections and Prematurity Study Group. Am J Obstet Gynecol. 1996 May;174(5):1618-21. doi: 10.1016/s0002-9378(96)70617-8.
- Fanchin R, Harmas A, Benaoudia F, Lundkvist U, Olivennes F, Frydman R. Microbial flora of the cervix assessed at the time of embryo transfer adversely affects in vitro fertilization outcome. Fertil Steril. 1998 Nov;70(5):866-70. doi: 10.1016/s0015-0282(98)00277-5.
- Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983 Jan;74(1):14-22. doi: 10.1016/0002-9343(83)91112-9.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
14 avril 1999
Achèvement de l'étude
18 novembre 2010
Dates d'inscription aux études
Première soumission
19 juin 2006
Première soumission répondant aux critères de contrôle qualité
19 juin 2006
Première publication (Estimation)
21 juin 2006
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
2 juillet 2017
Dernière mise à jour soumise répondant aux critères de contrôle qualité
30 juin 2017
Dernière vérification
18 novembre 2010
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- 999999023
- OH99-CH-N023
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .